Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2011-04-19 Director's Dealing
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Final Director`s Interest Notice 2 pages 171.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including holdings and contracts, and notes the date the director ceased to be a director. The content is focused on reporting personal share transactions or holdings by a company director. The document length is short (2369 characters) and it is a formal notice of director's interests rather than a financial report or announcement of a meeting or vote. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades).
2011-04-19 English
Appendix 3B 10 pages 495.5KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX rules and regulations. It details the issuance of convertible notes, the number and class of securities issued, terms of the notes, and application for quotation of additional securities on the ASX. The document is a formal announcement of a new securities issue and application for quotation, consistent with the Appendix 3B form used in Australian securities markets for new issue announcements. It does not contain financial statements, management discussion, or audit information. It is not a report but an announcement related to capital raising and securities issuance.
2011-03-30 English
CBio Reaches Important Clinical Trial Milestone 2 pages 181.5KB
Regulatory Filings Classification · 95% confidence The document is a company announcement from CBio Limited dated 28 March 2011. It announces the achievement of a clinical trial milestone (final dosing for the last patient in a rheumatoid arthritis trial) and new patent lodgements for an additional indication (lupus). The content is focused on operational updates related to clinical development and intellectual property, not on financial results, management changes, or regulatory filings. The document is relatively short (4337 characters) and is an announcement rather than a detailed report or transcript. There is no indication of financial data, earnings, or detailed management discussion. Therefore, the document fits best into the category of a general regulatory announcement or company announcement that does not fit other specific categories. According to the classification rules, such documents are best classified as Regulatory Filings (RNS).
2011-03-27 English
Appendix 3B Correction 11 pages 654.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'APPENDIX 3B CORRECTION' and is an announcement related to the Appendix 3B form, which is a 'New issue announcement, application for quotation of additional securities and agreement' as per ASX listing rules. The content includes details about securities issued, their classes, issue price, purpose, and application for quotation on the ASX. It is an administrative correction to a previously lodged Appendix 3B form. The document is not a financial report, earnings release, or management discussion but a regulatory announcement about securities issuance and quotation application. This fits the category of Share Issue/Capital Change announcements, which cover new share issues and capital structure changes. Therefore, the appropriate classification is SHA (Share Issue/Capital Change). The document length and detail support a high confidence in this classification.
2011-03-27 English
Appendix 3B- Exercise of Share Options 8 pages 479.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class and number of securities issued, issue price, purpose of the issue, and quotation application to the ASX. It references specific ASX rules and includes sections on securities not quoted, restricted securities, and convertible notes. The document is a formal announcement related to the issuance and quotation of new shares and securities, consistent with a capital raising or share issue event. It does not contain financial statements, management discussion, or audit information, nor is it a report or presentation. The document fits the definition of a 'Share Issue/Capital Change' announcement, which covers new share issues and capital structure changes.
2011-03-27 English
Section 708(A) Notice 1 page 156.6KB
Share Issue/Capital Change Classification · 100% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 regarding the issuance of fully paid ordinary shares by CBio Limited. It states the shares were issued without disclosure under Part 6D.2 of the Corporations Act and confirms compliance with relevant provisions. This is a regulatory announcement about a share issue event, specifically a notice related to share issuance without disclosure. The document is short (1054 characters) and is a formal notification rather than a full report. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2011-03-27 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.